Drug Profile
DW 908e
Alternative Names: DW-908eLatest Information Update: 12 May 2008
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Carboxylic acids; Indoles; Pyrrolidines
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 12 May 2008 Discontinued - Phase-I for Asthma in Japan (PO)
- 12 May 2008 Discontinued - Phase-I for Asthma in USA (PO)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc